DOWNSTREAM PROCESSING FEATURED ARTICLES
-
![nid93583-fenstermaker-ciesielski-32]( "Investigational Brain Cancer Vaccine To Be Tested In Phase I Roswell Park Study")
Investigational Brain Cancer Vaccine To Be Tested In Phase I Roswell Park StudyA new clinical research study at Roswell Park Cancer Institute(RPCI) will test a first-of-its-kind cancer “vaccine” that may prove effective against many forms of solid-tumor cancers.
-
![GettyImages-1147006093 Cleanroom Clean White Facility]( "The Real Threat To Biopharma Supply Chains: Bioprocessing Materials")
The Real Threat To Biopharma Supply Chains: Bioprocessing MaterialsThe COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive.
-
![Trisha Gladd]( "Merck Assesses Single Use: Does It Make Sense At A Large Scale?")
Merck Assesses Single Use: Does It Make Sense At A Large Scale?In an industry as conservative as the pharmaceutical industry, it is common practice to be adverse to new technologies because they are often viewed as too much of a risk. However, in this effort to play it safe, companies force themselves into a repetitive state of employing technologies that may not be the most efficient or effective. Rather than getting stuck in old habits — or conversely, jumping too quickly into new ones — Merck has put together a group of teams it calls the Technology Encouragement Collaborators, or TEC, to look at new technologies and determine whether or not to implement them.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Metal Removal From Fine Chemical Products
Metal contamination in various injectable or even oral medicines is a serious concern.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Rapid Screening Of A Cell-Based Assay For GLP-1 Receptor Using A Natural Product Library
Here we demonstrate the detection of GLP-1R binding through the incorporation of a homogeneous cell-based binding assay using HTRF Tag-lite® technology. By Brad Larson and Peter Banks, BioTek Instruments, Inc. and Nicolas Pierre, Suzanne Graham, Jean-Luc Tardieu, and François Degorce, Cisbio US, Inc.
-
Economic Analysis Of Single-Use Tangential Flow Filtration For Biopharmaceutical Applications Prior to creating an accurate economic model for TFF, a thorough understanding of the process where the TFF is used is needed. A process model is a valuable tool when properly executed and it must accurately include all critical aspects of the purification process. By Michael LaBreck, Mark Perreault, Novasep
-
Agilent Microarray Grant Application Support White Paper This guide offers an overview of Agilent’s microarray and SureSelect product offerings with ordering details to assist researchers with the details of grant submission.
-
Met One Sensors Resistant To Vaporous Hydrogen Peroxide (VHP) Pharmaceutical manufacturers often require an aseptic production environment to minimize the presence of microbes and their potential contamination of the manufactured product.
DOWNSTREAM PROCESSING PRODUCTS
The ReadyToProcess WAVE 25 rocker features integrated temperature sensors and load cells, designed for convenient handling and control of cell cultures up to 25 L. A filter heater is delivered with the system.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.